Dichlorphenamide Disease Interactions

The use of dichlorphenamide is contraindicated acidotic patients (hyperchloremic or respiratory).

The use of dichlorphenamide is contraindicated in adrenocortical insufficiency.

The use of dichlorphenamide is contraindicated in patients with hyponatremia or hypokalemia, or in conditions in which serum levels of sodium or potassium are depressed.

The use of dichlorphenamide is contraindicated in hepatic insufficiency.

Dichlorphenamide should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation as their acidosis may be increased.

The use of dichlorphenamide is contraindicated in renal failure.

Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels. Respiratory acidosis may be precipitated or increased in these patients. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis. Respiratory status should be monitored during therapy.

Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus. Routine glucose monitoring is recommended during therapy.

Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout. Elevated serum uric acid levels return to normal when the drug is discontinued. Monitoring of uric acid levels is recommended in these patients.